|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.
|
Celsion Corporation Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used Celsion Corporation email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Celsion Corporation customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.